Comparative Pharmacology
Head-to-head clinical analysis: CARDIZEM LA versus DYNACIRC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIZEM LA versus DYNACIRC.
CARDIZEM LA vs DYNACIRC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardizem LA (diltiazem) is a calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells during depolarization, leading to negative inotropic, chronotropic, and dromotropic effects. It dilates coronary and peripheral arteries, reducing systemic vascular resistance and myocardial oxygen demand.
Dynacirc (isradipine) is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance, thereby lowering blood pressure.
Oral, 180-360 mg once daily; initiate at 180 mg once daily, titrate to 240 mg, then 300 mg, then 360 mg once daily as needed.
2.5-10 mg orally once daily; titrate based on response. Maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life: 5-8 hours after oral administration. For extended-release formulations, the half-life is similar but the prolonged absorption phase results in sustained plasma concentrations.
Terminal elimination half-life is 7-8 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged up to 14 hours, necessitating dose adjustment.
Urine (2-4% unchanged, ~40% as metabolites); bile/feces (major route, ~60% as metabolites).
Primarily hepatic metabolism (CYP3A4) with <1% excreted unchanged in urine; approximately 60% of metabolites are excreted in feces via bile, and 35% in urine.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker